# Non-contrast Lung Perfusion Mapping Applied for New Insights in Cystic Fibrosis

> **NCT04467957** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Children's Hospital Medical Center, Cincinnati** · enrollment: 26 (estimated)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Initiation of CFTR Modulator
- **DRUG:** Hyperpolarized Xenon 129

## Key facts

- **NCT ID:** NCT04467957
- **Lead sponsor:** Children's Hospital Medical Center, Cincinnati
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-11-15
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04467957

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04467957, "Non-contrast Lung Perfusion Mapping Applied for New Insights in Cystic Fibrosis". Retrieved via AI Analytics 2026-05-20 from https://api.ai-analytics.org/clinical/NCT04467957. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*